Private Equity, VC & Investor
Creandum vs TA Ventures
Structured technology and market comparison · 2026
Direct Feature Comparison
Creandum · vs · TA VenturesEarly-stage technology venture capital firm supporting international founder growth.
Early-stage VC firm backing pre-seed and seed tech startups.
Analyze all overlapping signals and tech stacks for Creandum and TA Ventures
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Creandum and TA Ventures?
When comparing Creandum and TA Ventures, both platforms operate within the Private Equity, VC & Investor ecosystem. Creandum is positioned as Early-stage technology venture capital firm supporting international founder growth, whereas TA Ventures focuses on Early-stage VC firm backing pre-seed and seed tech startups. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Creandum and TA Ventures?
When evaluating Creandum and TA Ventures, enterprise buyers also consider other platforms in Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Creandum and TA Ventures compare?
Creandum is headquartered in United Kingdom (founded in 2003) with 50–200 employees. TA Ventures is based in Germany (founded in 2010) with <10 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Creandum vs TA Ventures
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Creandum
Recent Signals
- ·EU-Startups (European Venture)Financials
Creandum closes €668M fund for early-stage startups
Stockholm-based venture capital firm Creandum has closed its largest fund to date, Creandum VIII, at €668 million ($750 million), surpassing its previous €500 million ($560 million) Fund VII. The fund will support approximately 30 early-stage investments from pre-Seed to Series A over the next two years, with half the capital allocated to new investments and the rest for follow-on rounds. Creandum is focusing on AI-driven opportunities, having recently invested in startups like Lovable, Olix, Modal, and Black Forest Labs. The firm has opened a new office in San Francisco, tripled its team there in the past year, and plans to expand its US presence while maintaining a generalist strategy. The fund secured commitments from about 30 institutional investors across Europe and the US.
- Creandum closed its largest fund, Creandum VIII, at €668 million ($750 million), up from €500 million Fund VII.
- The fund will support approximately 30 investments from pre-Seed to Series A, with half for new investments and half for follow-ons.
- The fund focuses on AI, with portfolio companies including Lovable, Olix, Modal, and Black Forest Labs.
- ·EU-Startups (European Venture)AI in Enterprise
London's Ares Intelligence Raises €2.9M for AI Adoption Platform
London-based Ares Intelligence, a startup developing an evidence-based platform for AI transformation, has raised €2.9 million (£2.48 million) in a funding round led by Creandum and Lakestar, with participation from angel investors connected to Google DeepMind. The platform uses an AI interviewer to conduct confidential voice conversations with employees in over 70 languages, generating a prioritised roadmap for AI adoption within weeks. Founded in 2026 by Matt Falconer and Alfie Ranstead, the company addresses the challenge of where to start with AI automation. Ares counts enterprise customers across Europe and the US, including Tremonia, a Mercedes-Benz spin-out, which identified over 400 hours of manual work savings per month. The new capital will support expansion and bring its workforce intelligence approach to more businesses.
- Ares Intelligence raised €2.9 million (£2.48 million) in funding.
- The round was backed by Creandum and Lakestar, with participation from angels connected to Google DeepMind.
- The platform uses an AI interviewer to collect employee insights in over 70 languages.
- ·Tech.eu (European Tech & Deals)AI in Drug Development
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
- Atlas Bio raised a $10M Seed round led by Creandum, plus a $2.5M pre-Seed round led by First Momentum Ventures and LEA Partners, totaling $12.5M.
- The company's AI model is trained on roughly 2 million RNA readouts from human tissue.
- Atlas Bio is working with a top 10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow.
TA Ventures
Recent Signals
No recent market signals documented for TA Ventures in the current tracking window.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Creandum and TA Ventures share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks